Prenatal Screening, Diagnosis, and Pregnancy Management of Fetal Neural Tube Defects

Journal of Obstetrics and Gynaecology Canada

Volumn 36, Issue 10, 2014, Pages 927-939

  Douglas Wilson, R ^a   Audibert, Francois ^a   Brock, Jo Ann ^a   Campagnolo, Carla ^a   Carroll, June ^a   Cartier, Lola ^a   Chitayat, David ^a   Gagnon, Alain ^a   Johnson, Jo Ann ^a   Langlois, Sylvie ^a   Kim MacDonald, W ^a   Murphy Kaulbeck, Lynn ^a   Okun, Nanette ^a   Pastuck, Melanie ^a   Popa, Vanessa ^b  

^a NONE   (Canada)

^b NONE   (Canada)

Author keywords

Alpha fetoprotein; Amniocentesis; Anencephaly; Congenital anomalies; Magnetic resonance imaging; Myelomeningocele; Neural tube defects; Prenatal screening; Spina bifida; Ultrasound scan

Indexed keywords

ALPHA FETOPROTEIN;

ALPHA FETOPROTEIN BLOOD LEVEL; AMNIOCENTESIS; ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FETUS ECHOGRAPHY; FOLLOW UP; GENETICS; HEALTH CARE COST; HUMAN; MATERNAL BLOOD; MENINGOMYELOCELE; NEURAL TUBE DEFECT; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTETRIC DELIVERY; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL SCREENING;

EID: 84925231716     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30444-8     Document Type: Article

References (109)

1. Frey L., Hauser W.A. Epidemiology of neural tube defects. Epilepsia 2003, 44(3):4-13.
2. Gucciardi E., Pietrusiak M., Reynolds D.L., Rouleau J. Incidence of neural tube defects in Ontario 1986-1999. CMAJ 2002, 167(3):237-240.
3. De Marco P., Merello E., Rossi A., Piatelli G., Cama A., Kibar Z., Capra V. FZD6 is a novel gene for human neural tube defects. Human Mutation 2011, 3:384-390.
4. Van Allen M.I., Boyle E., Thiessen P., McFadden D., Cochrane D., Chambers G.K., et al. The impact of prenatal diagnosis on neural tube defect (NTD) pregnancy versus birth incidence in British Columbia. J Appl Genet 2006, 47:151-158.
5. Wilson R.D., Johnson J.A., Wyatt P., Allen V., Gagnon A., Langlois S., et al. Preconceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2007, 29:1003-1026.
6. De Wals P., Tairou F., Van Allen M.I., Uh S., Lowry R.B., Sibbald B., et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007, 357(2):135-142.
7. Lu Q.B., Wang Z.P., Gong R., Sun X.H., Gao L.J., Zhao Z.T. Investigation of ultrasound screening efficiency for neural tube defects during pregnancy in rural areas of China. Public Health 2011, 125:639-644.
8. Kokalj T.S., Rejc B., Gersak K. Incidence and prevention of neural tube defects in Slovenia. Eur J Obstet Gynecol 2011, 156:119-120.
9. Cameron M., Moran P. Prenatal screening and diagnosis of neural tube defects. Prenatal Diagnosis 2009, 29:402-411.
10. Bamforth F.J. Laboratory screening for genetic disorders and birth defects. Clin Biochem 1994, 27:333-342.
11. Vintzileos A.M., Ananth C.V., Fisher A.J., Smulian J.C., Day-Salvatore D., Beazoglou T., et al. Cost-benefit analysis of targeted ultrasonography for prenatal detection of spina bifida in patients with an elevated concentration of second-trimester maternal serum a-fetoprotein. Am J Obstet Gynecol 1999, 180:1227-1233.
12. Harris R.A., Washington A.E., Nease R.F., Kupperman M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 2004, 363:276-282.
13. EUROCAT Working Group Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. Epistemiol Community Health 1991, 4552-4558.
14. Cuckle H.S., Wald N.J., Cuckle P.M. Prenatal screening and diagnosis of neural tube defects in England and Wales in 1985. Prenat Diagnos 1989, 9:393-400.
15. Roberts N., Bhide A. Ultrasound prenatal diagnosis of structural abnormalities. Obstet Gynaecol Reprod Med 2007, 17:1-8.
16. Norem C.T., Schoen E.J., Walton D.L., Krieger R.C., O'Keefe J., To T.T., et al. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening. Obstet Gynecol 2005, 106:747-752.
17. Driscoll D.A., Gross S.J. Screening for fetal aneuploidy and neural tube defects. Genet Med 2009, 11:818-821.
18. Chodirker B.N., Cadrin C., Davies G.A.L., Summers A.M., Wilson R.D., Winsor E.J.T., et al. Canadian guidelines for prenatal diagnosis. Part 1: genetic indicators for prenatal diagnosis. SOGC Clinical Practice Guidelines, No. 105, June 2001. J Obstet Gynaecol Can 2001, 23:525-531.
19. Johnson J.A., Summers A. Prenatal genetic screening for Down syndrome and open neural tube defects using maternal serum marker screening. J Obstet Gynaecol Can 1999, 21:887-891.
20. Wald N.J., Hackshaw A., Stone R., Densem J. Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. Prenat Diagn 1993, 13:1047-1050.
21. Sohn Y.S., Kim M.J., Kwon J.Y., Kim Y.H., Park Y.W. The usefulness of fetal MRI for prenatal diagnosis. Yonsei Med J 2007, 48:671-677.
22. Pugash D., Brugger P.C., Bettelheim D., Prayer D. Prenatal ultrasound and fetal MRI: the comparative value of each modality in prenatal diagnosis. Eur J Radiol 2008, 68:214-226.
23. Delisle M., Wilson R.D. First trimester prenatal diagnosis: amniocentesis. Semin Perinatol 1999, 23:414-423.
24. Zambelli H., Carelli E., Honorato D., Marba S., Coelho G., Carnevalle A., et al. Assessment of neurosurgical outcome in children prenatally diagnosed with myelomeningocele and development of a protocol for fetal surgery to prevent hydrocephalus. Childs Nerv Syst 2007, 23:421-425.
25. Ewigman B.G., Crane J.P., Frigoletto F.D., LeFevre M.L., Bain R.P., McNellis D. Effect of prenatal ultrasound screening on perinatal outcome. N Engl J Med 1993, 329:821-827.
26. Saari-Kemppainen A., Karjalainen O., Ylostalo P., Heinonen O. Ultrasound screening and perinatal mortality: Controlled trial of systematic one-stage screening in pregnancy. Int J Gynaecol Obstet 1991, 35:100.
27. Saleem S.N., Said A.H., Abdel-Raouf M., El-Kattan E.A., Zaki M.S., Madkour N., et al. Fetal MRI in the evaluation of fetuses referred for sonographically suspected neural tube defects (NTDs)-impact on diagnosis and management decision. Neuroradiology 2009, 51:761-772.
28. Boulet S.L., Yang Q., Mai C., Kirby R.S., Collins J.S., Robbins J.M., National Birth Defects Prevention Network, et al. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol 2008, 82:527-532.
29. Shurtleff D.B., Luthy D.A., Nyberg D.A., Benedetti T.J., Mack L.A. Meningomyelocele: management in utero and post natum. Ciba Found Symp 1994, 181:270-286.
30. Hunt G.M. The median survival time in open spina bifida. Dev Med Child Neurol 1997, 39:568.
31. Manning S.M., Jennings R., Madsen J.R. Pathophysiology, prevention and potential treatment of neural tube defects. Ment Retard Dev Disabil Res Rev 2000, 6:6-14.
32. Ghi T., Pilu G., Falco P., Segata M., Carletti A., Cocchi G., et al. Prenatal diagnosis of open and closed spina bifida. Ultrasound Obstet Gynecol 2006, 28:899-903.
33. Kanit H., Özkan A.A., Öner S.R., Ispahi C., Endrikat J.S., Ertan K. Chromosomal abnormalities in fetuses with ultrasonographically detected neural tube defects. Clin Dysmorphol 2012, 20:190-193.
34. Drugan A., Johnson M.P., Dvorin E., Moody J., Krivchenia E.L., Schwartz D., et al. Aneuploidy with neural tube defects: another reason for complete evaluation in patients with suspected ultrasound anomalies or elevated maternal serum alpha-fetoprotein. Fetal Diagn Ther 1989, 4:88-92.
35. Harmon J.P., Ak Hiett, Palmer C.G., Golichowski A.M. Prenatal ultrasound detection of isolated neural tube defects is cytogenetic evaluation warranted?. Obstet Gynecol 1995, 86:595-599.
36. Hume R.F., Drugan A., Reichler A., Lampinen J., Martin L.S., Johnson M.P., et al. Aneuploidy among prenatally detected neural tube defects. Am J Med Genet 1996, 61:171-173.
37. Kennedy D., Chitayat D., Winsor E.J., Silver M., Toi A. Prenatally diagnosed neural tube defects: ultrasound, chromosome, and autopsy or postnatal findings in 1212 cases. Am J Med Genet 1998, 77:317-321.
38. Chen C.P. Syndromes, disorders and maternal risk factors associated with neural tube defects (IV). Taiwan J Obstet Gynecol 2008, 47:141-150.
39. De Marco P., Merello E., Cama A., Kibar Z., Capra V. Critical review: human neural tube defects: genetic causes and prevention. Biofactors 2011, 37:261-268.
40. Alfarra H.Y., Alfarra S.R., Sadiq M.F. Neural tube defects between folate metabolism and genetics. Ind J Hum Genet 2011, 17(3):126-131.
41. Aneji C.N., Northrup H., Au K.S. Deep sequencing study of the MTHFR gene to identify variants associated with myelomeningocele. Birth Defects Res A Clin Mol Teratol 2012, 94:84-90.
42. Wang X.W., Luo Y.L., Wang W., Zhang Y., Chen Q., Cheng L.Y. Association between MTHFR A1298C polymorphism and neural tube defect susceptibility: a meta-analysis. Am J Obstet Gynecol 2012, 251:e1-e7.
43. Cargill Y. Morin L; Society of Obstetricians and Gynaecologists of Canada. Diagnostic Imaging Committee. Content of a complete routine second trimester obstetrical ultrasound examination and report. SOGC Clinical Practice Guidelines, No. 223, March 2009. J Obstet Gynaecol Can 2009, 31:272-275.
44. Dashe J.S., Twickler D.M., Santos-Ramos R., McIntire D.D., Ramus R.M. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound. Am J Obstet Gynecol 2006, 195:1623-1628.
45. Benn P.A., Borgida A., Home D., Briganti S., Collins R., Rodis J.F. Down syndrome and neural tube defect screening-the value of using gestational age by ultrasonography. Am J Obstet Gynecol 1997, 176:1056-1061.
46. Lee W., Chaiworapongsa T., Romero R., Williams R., McNie B., Johnson A., et al. A diagnostic approach for the evaluation of spina bifida by three-dimensional ultrasonography. J Ultrasound Med 2002, 21:619-626.
47. Malhotra N., Rao J.P., Malhotra J., Malhotra N. Ultrasound for screening fetal malformations-has 3-D made a difference?. J SAFOG 2012, 2:7-10.
48. Garne E., Dolk H., Loane M., Boyd P.A. EUROCAT website data on prenatal detection rates of congenital anomalies. J Med Screen 2010, 17:97-98.
49. den Hof MC Van, Wilson R.D., SOGC Diagnostic Imaging Committee, SOGC Imaging Committee Fetal soft markers in obstetric ultrasound. SOGC Clinical Practice Guidelines, No. 162, June 2005. J Obstet Gynaecol Can 2005, 27:592-612.
50. Gagnon A., Wilson R.D., Allen V.M., Audibert F., Blight C., Brock J.A., Society of Obstetricians and Gynaecologists of Canada, et al. Evaluation of prenatally diagnosed structural congenital anomalies. SOGC Committee Opinion, No. 234, Sept 2009. J Obstet Gynaecol Can 2009, 31:875-881.
51. Wald N.J., Cuckle H., Brock J.H., Peto R., Polani P.E., Woodford F.P. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy: report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects. Lancet 1977, 309:1323-1332.
52. Taplin S.H., Thompson R.S., Conrad D.A. Cost-justification analysis of prenatal maternal serum alpha-feto protein screening. Med Care 1988, 26:1185-1202.
53. Heckerling P.S., Verp M.S. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing. Med Care 1994, 32:863-880.
54. Bredaki F.E., Wright D., Akolekar R., Cruz G., Nicolaides K.H. Maternal serum alpha-fetoprotein in normal pregnancy at 11-3 weeks' gestation. Fetal Diagn Ther 2011, 30:274-279.
55. Bredaki F.E., Poon L.C., Birdir C., Escalante D., Nicolaides K.H. First-trimester screening for neural tube defects using alpha-fetoprotein. Fetal Diagn Ther 2012, 31:109-114.
56. Stratmeyer M.E., Greenleaf J.F., Dalecki D., Salvesen K.A. Fetal ultrasound: mechanical effects. J Ultrasound Med 2008, 27:597-605.
57. Salomon L.J., Ville Y. Quality control of prenatal ultrasound. Ultrasound Review 2005, 5:297-303.
58. Roberts C.J., Hibbard B.M., Roberts E.E., Ecans K.T., Laurence K.M., Robertson I.B. Diagnostic effectiveness of ultrasound in detection of neural tube defect: the South Wales experience of 2509 scans (1977-982) in high-risk mothers. Lancet 1983, 2:1068-1069.
59. Hosny I.A., Elghawabi H.S. Ultrafast MRI of the fetus: an increasingly important tool in prenatal diagnosis of congenital anomalies. Magn Reson Imaging 2010, 28:1431-1439.
60. Cameron M., Moran P. Prenatal screening and diagnosis of neural tube defects. Prenat Diagn 2009, 29:402-411.
61. Chaoui R., Benoit B., Mitkowska-Wozniak H., Heling K.S., Nicolaides K.H. Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11-3 week scan. Ultrasound Obstet Gynecol 2009, 34:249-252.
62. Lachmann R., Picciarelli G., Moratalla J., Greene N., Nicholaides K.H. Frontomaxillary facial angle in fetuses with spina bifida at 11-3 weeks' gestation. Ultrasound Obstet Gynecol 2010, 36:268-271.
63. Scheier M., Lachmann R., Petros M., Nicolaides K.H. Three-dimensional sonography of the posterior fossa in fetuses with open spina bifida at 11-13 weeks' gestation. Ultrasound Obstet Gynecol 2011, 38:625-629.
64. Lachmann R., Chaoui R., Moratalla J., Picciarelli G., Nicolaides K.H. Posterior brain in fetuses with open spina bifida at 11-13 weeks. Prenat Diagn 2011, 31:103-106.
65. Loureiro T., Ushakov F., Montenegro N., Gielchinsky Y., Nicolaides K.H. Cerebral ventricular system in fetuses with open spina bifida at 11-13 weeks' gestation. Ultrasound Obstet Gynecol 2012, 39:620-624.
66. Coakley F.V., Glenn O.A., Qayyum A., Barkovich A.J., Goldstien R., Filly R.A. Fetal MRI: a developing technique for the developing patient. AJR Am J Roentgenology 2004, 182:243-252.
67. Garel C. Fetal MRI: what is the future?. Ultrasound Obstet Gynecol 2008, 31:123-128.
68. Glenn O.A., Cuneo A.A., Barkovich A.J., Hashemi Z., Bartha A.I., Xu D. Malformations of cortical development- diagnostic accuracy of fetal MR imaging. Radiology 2012, 263(3):843-855.
69. Girard N., Chaumoitre K., Chapon F., Pineau S., Barberet M., Brunel H. Fetal magnetic resonance imaging of acquired and developmental brain anomalies. Semin Perinatol 2009, 33:234-250.
70. Ljubic A., Cetkovic A., Mikic A.N., Stamenkovic J.D., Jovanovic I., Opincal T.S., et al. Ultrasound vs MRI in diagnosis of fetal and maternal complications. Ultrasound Review 2001, 5(2/3):231-242.
71. Cannie M., Jani J., Dymarkowski S., Deprest J. Fetal magnetic resonance imaging: luxury or necessity?. Ultrasound Obstet Gynecol 2006, 27:471-476.
72. Al-Mukhtar A., Kasprian G., Schmook M.T., Brugger P.C., Prayer D. Diagnostic pitfalls in fetal brain MRI. Semin Perinatol 2009, 33:251-258.
73. Sutton L.N. Fetal surgery for neural tube defects. Best Pract Res Clin Obstet Gynaecol 2008, 22:175-188.
74. Adzick N.S., Thom E.A., Spong C.Y., Brock J.W., Burrows P.K., Johnson M.P., et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011, 364:993-1004.
75. Patenaude Y., Pugash D., Lim K., Morin L., SOGC Diagnostic Imaging Committee The use of Magnetic Resonance Imaging in the obstetric patient. SOGC Clinical Practice Guidelines, No. 306, April 2014. J Obstet Gynaecol Can 2014, 36:349-355.
76. Bulas D. Fetal magnetic resonance imaging as a complement to fetal ultrasonography. Ultrasound Q 2007, 23:3-22.
77. Williams F., Griffiths P.D. Spinal neural tube defects on in utero MRI. Clin Radiol 2013, 68:e715-e722.
78. Ben-Sira L., Garel C., Malinger G., Constantini S. Prenatal diagnosis of spinal dysraphism. Childs Nerv Syst 2013, 29:1541-1552.
79. Körner H., Rodriguez L., Yero J.L.F., Schulze M., Horn A., Heredero L., et al. Maternal serum alpha-fetoprotein screening for neutal tube defects and other disorders using an ultramicro-ELISA. Collaborative study in Cuba and in the German Democratic Republic. Hum Genet 1986, 73:60-63.
80. Widlund K.F., Gottvall T. Routine assessment of amniotic fluid alpha-fetoprotein in early second-trimester amniocentesis is no longer justified. Acta Obstet Gynecol Scand 2007, 86:67-71.
81. Wapner R.J., Martin C.L., Levy B., Ballif B.C., Eng C.M., Zachary J.M., et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012, 367:2175-2184.
82. Reddy U.M., Page G.P., Saade G.R., Silver R.M., Thorsten V.R., Parker C.B., et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med 2012, 367:2185-2193.
83. Talkowski M.E., Ordulu Z., Pillalamarri V., Benson C.B., Blumenthal I., Connolly S., et al. Clinical diagnosis by whole-genome sequencing of a prenatal sample. N Engl J Med 2012, 367:2226-2232.
84. Shumway J.B., Greenspoon J.S., Khouzami A.N., Platt L.D., Blakemore K.J. Amniotic fluid alpha fetoprotein (AFAFP) and maternal serum alpha fetoprotein (MSAFP) in abdominal pregnancies: correlation with extent and site of placental implantation and clinical implications. J Matern Fetal Med 1996, 5:120-123.
85. Laurence K.M., Elder G., Evans K.T., Hibbard B.M., Hooles M., Roberts C.J. Should women at high risk of neural tube defect have an amniocentesis?. J Med Genet 1985, 22:457-461.
86. Nizard J. Amniocentesis: technique and education. Curr Opin Obstet Gynecol 2010, 22:152-154.
87. Wilson R.D., Langlois S., Johnson J.A., Genetics Committee and CCMG Prenatal Diagnosis Committee of the Society of Obstetricians and Gynaecologists of Canada Mid-trimester amniocentesis fetal loss rate. SOGC Committee Opinion, No. 194, July 2007. J Obstet Gynaecol Can 2007, 29:586-590.
88. Kooper A.J., de Bruijn D., van Ravenwaaij-Arts C.M.A., Faas B.H.W., Creemers J.W.T., Thomas C.M.G., et al. Fetal anomaly scan potentially will replace routine AFAFP assays for the detection of neural tube defects. Prenat Diagn 2007, 27:29-33.
89. Król M., Sibiński M., Stefanski M., Synder M. Assessment of life quality in children with spina bifida. Chir Narzadow Ruchu Ortop Pol 2011, 76:52-55.
90. Barf H.A., Post M.W., Verhoef M., Jennekens-Schinkel A., Gooskens R.H., Prevo A.J. Life satisfaction of young adults with spina bifida. Dev Med Child Neurol 2007, 49:458-463.
91. Hunt G.M., Oakeshott P. Outcome in people with open spina bifida at age 35: prospective community based cohort study. BMJ 2003, 326:1365-1366.
92. Bowman R.M., McLone D.G., Grant J.A., Tomita T., Ito J.A. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg 2001, 34:114-120.
93. Yi Y., Lindemann M., Colligs A., Snowball C. Economic burden of neural tube defects and impact of prevention with folic acid: a literature review. Eur J Pediatr 2011, 170:1391-1400.
94. ACOG Committee on Practice Bulletins.Neural tube defects.ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician-Gynecologists. No 44, July 2003 (Replaces Committee Opinion Number 252, March 2001). Obstet Gynecol 2003, 102:203-213.
95. Vindla S., Sahota D.S., Coppens M., James D.K. Computerized analysis of behavior in fetuses with congenital abnormalities. Ultrasound Obstet Gynecol 1997, 9:302-309.
96. Bowman R.M., McLone D.G., Grant J.A., Tomita T., Ito J.A. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg 2001, 34:114-120.
97. Cochrane D., Aronyk K., Sawatzky B., Wilson D., Steinbok P. The effects of labour and delivery on spinal cord function and ambulation in patients with meningomyelocele. Child Nerv Syst 1991, 7:312-315.
98. Bensen J.T., Dillard R.G., Burton B.K. Open spina bifida: does cesarean section delivery improve diagnosis?. Obstet Gynecol 1988, 71:532-534.
99. Sakala E.P., Andree I. Optimal route of delivery for meningomyelocele. Obstet Gynecol Surv 1990, 45:209-212.
100. Hill A.E., Beattie F. Does caesarean section delivery improve neurological outcome in open spina bifida?. Eur J Pediatr Surg 1994, 4(Suppl 1):32-34.
101. Merrill D.C., Goodwin P., Burson J.M., Sato Y., Williamson R., Weiner C.P. The optimal route of delivery for fetal meningomyelocele. Am J Obstet Gynecol 1998, 179:235-240.
102. Luthy D.A., Wardinsky T., Shurtleff D.B., Hollenback K.A., Hickok D.E., Nyberg D.A., et al. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. N Engl J Med 1991, 324:662-666.
103. Simpson J.L., Greene M.F. Fetal surgery for myelomeningocele?. N Engl J Med 2011, 364:1076-1077.
104. Dickens B.M., Cook R.J. Ethical and legal issues in reproductive health. Legal and ethical issues in fetal surgery. Int J Gynaecol Obstet 2011, 115:80-83.
105. Barry S. Quality of life and myelomeningocele: an ethical and evidence-based analysis of the Groningen protocol. Pediatr Neurosurg 2010, 46:409-414.
106. Boyd P.A., DeVigan D., Khoshnood B., Loane M., Garne E., Dolk H., EUROCAT working group Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG 2008, 115:689-696.
107. Désilets V., Oligny L.L., Genetics and Family Physicians Advisory Committees of the Society of Obstetricians and Gynaecologists of Canada Fetal and perinatal autopsy in prenatally diagnosed fetal abnormalities with normal karyotype. SOGC Technical Update, No. 267, October 2011. J Obstet Gynaecol Can 2011, 33:1047-1057.
108. Miller E.C., Liu N., Wen S.W., Walker M. Why do Canadian women fail to achieve optimal pre-conceptional folic acid supplementation? An observational study. J Obstet Gynaecol Can 2011, 33:1116-1123.
109. Woolf S.H., Battista R.N., Angerson G.M., Logan A.G., Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003, 169:207-208.